A Twenty-Four Week, Open-Label, Non-Comparative, Multi-Center Study to Assess the Efficacy and Tolerability of an Aliskiren-Based Treatment Algorithm in Patients With Mild to Moderate Hypertension.

Trial Profile

A Twenty-Four Week, Open-Label, Non-Comparative, Multi-Center Study to Assess the Efficacy and Tolerability of an Aliskiren-Based Treatment Algorithm in Patients With Mild to Moderate Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 26 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Actual patient number (256) added as reported by ClinicalTrials.gov.
    • 26 Aug 2009 Actual end date (Aug 2009 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top